Rani Therapeutics Holdings Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has developed a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to a 500%-plus higher drug payload than Rani’s existing oral biologics capsule.   In preclinical testing, RaniPill HC demonstrated successful delivery of adalimumab and achieved high bioavailability.   “The RaniPill HC gives us the potential to deliver a much ...